Form 4: Stoke Therapeutics GC Sells Shares Under 10b5-1 Plan

Stoke Therapeutics General Counsel Jonathan Allan sold 3,978 shares of common stock on December 8, 2025, under a pre-arranged trading plan.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported the sale of 3,978 shares of common stock.
• The transactions occurred on December 8, 2025, and were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024.
• 1,300 shares were sold at a weighted average price of $31.5956 per share, with prices ranging from $31.27 to $32.14.
• An additional 2,678 shares were sold at a weighted average price of $32.6128 per share, with prices ranging from $32.29 to $33.19.
• Following these transactions, Jonathan Allan directly beneficially owns 11,831 shares of Stoke Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it represents insider selling, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned diversification or liquidity event rather than a reaction to new, negative information. This mitigates the potential negative signal of insider selling.

Negatives

• The sale of 3,978 shares by a key executive, the General Counsel, reduces insider ownership.
• While executed under a 10b5-1 plan, insider selling can sometimes be perceived by the market as a lack of confidence or a signal that the stock may be fully valued.

Industry Context

This transaction is specific to Stoke Therapeutics and its General Counsel, Jonathan Allan, and does not directly reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders may perceive the insider sale as a minor negative signal, potentially influencing short-term sentiment, although the 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

The sale by a General Counsel, while notable, was executed under a pre-arranged 10b5-1 trading plan, suggesting it's a planned diversification or liquidity event rather than a reaction to new, negative information. Without further context or a pattern of significant insider selling, a 'hold' recommendation is appropriate, advising investors to monitor future insider activity and company fundamentals.

Keywords

Stoke Therapeutics, STOK, insider trading, Form 4, stock sale, Jonathan Allan, General Counsel, 10b5-1 plan